OncLiveBeyond CARs: New T-Cell Strategies Take Center StageOncLiveIn the case of the 2 newly approved therapies, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), the transduction payload consists of single-chain variable fragments der… Continue reading
Brainstorm Health: Human CRISPR Trials, Hospital Run Drug Company, CHIP ExtensionFortuneDrug makers have largely ignored the public firestorm surrounding high drug prices. Now, a coalition of major U.S. hospitals is taking the matter into its own hands… Continue reading
|
Protein designed entirely from scratch functions in cells as a genuine enzyme
Phys.Org “One is for the life that remains to be discovered on Earth. Perhaps one day, we’ll find a natural enzyme that looks like Syn-F4 but takes the place of Fes in some microorganism or other. At least now, we’ll know to look. Another implication is for … |
Digital Trends |
Stem cell breakthrough may give people with paralysis their sense of touch back
Digital Trends For someone without a severe spinal cord injury (SCI), trying to wrap your head around what it would be like to experience is next to impossible. While most of us might focus on the mobility difficulties such a condition may cause, it’s easy to forget … |
Life Sciences Intellectual Property Review |
UPDATE: Rockefeller, Broad Settle CRISPR IP Dispute; EPO Denies Broad European Patent
GenomeWeb This article has been updated from a previous version to include a statement from ERS Genomics on the EPO’s decision regarding the Broad Institute’s European patents. NEW YORK (GenomeWeb) – Rockefeller University and the Broad Institute said this week … CRISPR: the gene editing tool making the world go roundLexology Mixed views on Broad’s fate after EPO revokes CRISPR patentLife Sciences Intellectual Property Review Major blow for Broad Institute in European CRISPR patent disputeThe Pharma Letter |
|
Designed enzyme rescues live bacteria | January 22, 2018 Issue …
The Biological SCENE Syn-F4 catalyzes the conversion of ferric enterobactin to monomer, dimer, and trimer products, just as the native enzyme ferric enterobactin esterase does. It’s hard to get proteins designed from scratch, called de novo proteins, to catalyze reactions … |